Investigative ophthalmology & visual science · 2025
Diverse-Ancestry GWAS of Age-Related Macular Degeneration on 16,108 Examined Cases and 18,038 Controls.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gorski Mathias, Grunin Michelle, Herold Janina M, Fröhlich Benedikt, Behr Merle, Wheeler Nicholas, Bush William S, Song Yeunjoo E, Zhu Xiaofeng, Blanton Susan H, Pericak-Vance Margaret A, Heid Iris M, Haines Jonathan L, International Age-Related Macular Degeneration Genomics Consortium
Аннотация
PURPOSE: In 2016, the International Age-related Macular Degeneration Genomics Consortium analyzed data from approximately 50,000 individuals (IAMDGC 1.0) and identified 52 variants across 34 loci associated with advanced AMD (adAMD) in individuals of European ancestry and did not include diverse ancestries, fine-mapping per ancestry, or a predictive model with/without the contributions of one lead genetic risk locus, CFH. Therefore, we analyzed full cross-ancestry IAMDGC data, utilizing the newest imputation panel, and identified genetic risk loci across and between ancestries contributing to AMD.
METHODS: In this IAMDGC 2.0 analysis, we included cross-ancestry data via custom exome chip imputed genome-wide via TOPMedv2, in 16,108 ophthalmologically confirmed adAMD cases and 18,038 examined AMD-free controls. We included both male and female subjects and four diverse ancestries. Data were analyzed from June 2021 to May 2024.
RESULTS: Utilizing diverse ancestry data (cases/controls = 15,616/16,723 European, 50/357 African, 207/322 Asian, and 235/636 Other), we identified 28 loci at P < 5 × 10-8, including 2 additional AMD loci compared to IAMDGC 1.0 (SERPINA1 and CPN1). Fine-mapping supported one ancestry-shared signal around HTRA1/ARMS2 and nine signals around CFH without African ancestry contribution. The 52-variant genetic risk score with and the 44-variant score without CFH predicted adAMD in all ancestries (area under the curve [AUC] = 0.80/0.75, 0.65/0.64, and 0.80/0.79, respectively).
CONCLUSIONS: Our results indicate that the genetic underpinning of adAMD is mostly shared between ancestries. We also identify the CFH variant as being less relevant in specific ancestries, indicating a difference in pathogenic burden between ancestries. We increased the available genomic data for AMD over 300-fold with the IAMDGC 2.0 imputation, making it a valuable resource for further AMD genetic analysis.
METHODS: In this IAMDGC 2.0 analysis, we included cross-ancestry data via custom exome chip imputed genome-wide via TOPMedv2, in 16,108 ophthalmologically confirmed adAMD cases and 18,038 examined AMD-free controls. We included both male and female subjects and four diverse ancestries. Data were analyzed from June 2021 to May 2024.
RESULTS: Utilizing diverse ancestry data (cases/controls = 15,616/16,723 European, 50/357 African, 207/322 Asian, and 235/636 Other), we identified 28 loci at P < 5 × 10-8, including 2 additional AMD loci compared to IAMDGC 1.0 (SERPINA1 and CPN1). Fine-mapping supported one ancestry-shared signal around HTRA1/ARMS2 and nine signals around CFH without African ancestry contribution. The 52-variant genetic risk score with and the 44-variant score without CFH predicted adAMD in all ancestries (area under the curve [AUC] = 0.80/0.75, 0.65/0.64, and 0.80/0.79, respectively).
CONCLUSIONS: Our results indicate that the genetic underpinning of adAMD is mostly shared between ancestries. We also identify the CFH variant as being less relevant in specific ancestries, indicating a difference in pathogenic burden between ancestries. We increased the available genomic data for AMD over 300-fold with the IAMDGC 2.0 imputation, making it a valuable resource for further AMD genetic analysis.